Lilly & Covance - Diabetes Drug Discovery Partnership in China
SHANGHAI, May 30, 2012 /PRNewswire/ -- "Eli Lilly and Company (NYSE: LLY) today announced it has officially opened the Lilly China Research and Development Center (LCRDC), a key component of its significant and sustainable commitment to China."
"The goal of the LCRDC is to discover innovative diabetes medicines with novel mechanisms of action that can be tailored specifically for the Chinese population to delay the progression of the disease. Affecting nearly 90 million Chinese, diabetes is a significant national public health problem, due in part to longer life expectancies, dietary changes and a sedentary lifestyle emerging in China. Differences in the genetic makeup of Asian patients may also play a role in diabetes development and progression, and exploring these differences is a priority for the LCRDC. The LCRDC, which employs approximately 150 scientists and staff hired primarily from China, is the latest in a series of significant research and development (R&D) investments exemplifying Lilly's commitment to innovation, diabetes care and improving outcomes for individual patients around the world."
Click here for full article and to learn more about the Lilly and Covance agreement to establish a diabetes discovery partnership in China.
